Cardiovascular Risk of NSAIDs: Time to Translate Knowledge into Practice

PLoS Medicine

Volumn 10, Issue 2, 2013, Pages

  Reddy, K Srinath ^a   Roy, Ambuj ^b  

^a PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; ROFECOXIB; THROMBOXANE A2;

ARTICLE; ATHEROGENESIS; BLOOD CLOTTING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); OSTEOARTHRITIS; PAIN; PUBLIC HEALTH; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC);

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; COMMERCE; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INDUSTRY; DRUGS, ESSENTIAL; HUMANS; PHARMACOPOEIAS AS TOPIC;

EID: 84874483579     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001389     Document Type: Article

References (14)

1. McGettigan P, Henry D, (2013) Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 10: e1001388 doi:10.1371/journal.pmed.1001388.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528.
3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102.
4. Singh S, Wu O, Langhorne P, Madhok R, (2006) Risk of acute myocardial infarction with non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 8: R153 doi:10.1186/ar2047.
5. McGettigan P, Henry D, (2006) Cardiovascular risk and inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective and non-selective inhibitors of cyclo-oxygenase. JAMA 296: 1633-1644 doi:10.1001/jama.296.13.jrv60011.
6. Kearney P, Baigent C, Goodwin J, Halls H, Emberson J, Patrono C, (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302-1308.
7. Fosbøl EL, Folke F, Jacobsen S, Rasmussen JN, Sørensen R, et al. (2010) Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 3: 395-405.
8. García Rodríguez LA, Tacconelli S, Patrignani P, (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52: 1628-1636.
9. Trelle S, Reichenbach S, Wandel S, et al. (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: A network meta-analysis. BMJ 342: c7086 doi:10.1136/bmj.c7086.
10. Grosser T, Fries S, FitzGerald GA, (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15.
11. Government of India, Ministry of Health & Family Welfare (2011) National list of essential medicines of India. Available: http://cdsco.nic.in/National%20List%20of%20Essential%20Medicine-%20final%20copy.pdf. Accessed 28 November 2012.
12. Laing R, Waning B, Gray A, Ford N, 'tHoen E, (2003) 25 years of the WHO essential medicines lists: progress and challenges. Lancet 361: 1723-1729.
13. Reddy KS, (2004) Cardiovascular disease in non-Western countries. N Engl J Med 350: 2438-2440.
14. WHO (2011) Global status report on noncommunicable diseases 2010. Geneva: World Health Organization. Available: http://www.who.int/nmh/publications/ncd_report_full_en.pdf. Accessed 28 November 2012.